Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin in CTCL and PTCL
NCT00007345Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2001
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of romidepsin in cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) (7 cohorts), sponsored by National Cancer Institute. Primary endpoints: Overall Response Rate up to 56.5 days, Complete Response Rate up to 56.5 days and 1 more. Started Mar 2001; status: completed.
02
Drugs
romidepsin
03
Conditions
cutaneous T-cell lymphoma (CTCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT00007345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00007345.